Post-CDK4/6 inhibitor therapy in HR+/HER2– advanced breast cancer: expanding options and persisting uncertainties
Endocrine treatment in combination with CDK4/6 inhibitors represents the mainstay of first-line palliative treatment in HR+/HER2– breast cancer. The treatment landscape after progression on CDK4/6 inhibitors has evolved into a complex and rapidly evolving field, driven by novel endocrine and targeted agents, new combin...